Results 41 to 50 of about 3,923 (195)
Bicyclic Boronates as Potent Inhibitors of AmpC, the Class C β-Lactamase from Escherichia coli
Resistance to β-lactam antibacterials, importantly via production of β-lactamases, threatens their widespread use. Bicyclic boronates show promise as clinically useful, dual-action inhibitors of both serine- (SBL) and metallo- (MBL) β-lactamases.
Pauline A. Lang +12 more
doaj +1 more source
The review aims to review the positioning of meropenem-vaborbactam in clinical practice, taking into consideration the characteristics of other available drugs, namely ceftazidime-avibactam, plazomicin, and colistin.
Evangelos J. Giamarellos-Bourboulis (8774799) +2 more
core +1 more source
Activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates in Iran [PDF]
We evaluated the activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates.
Nikkhahi, Farhad +16 more
core +1 more source
Background: Multi-drug resistant Enterobacterales is a growing health threat. Imipenem/relebactam and meropenem/vaborbactam, are not clinically used in Taiwan and the susceptibility is lack from routine laboratory tests.
Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
doaj +1 more source
Chemical structures of vaborbactam and β-lactams, a monobactam and a DBO inhibitor.
Vaborbactam, ceftazidime, cefoperazone, meropenem, aztreonam, and zidebactam are represented. The R1-and R2-groups for ceftazidime are indicated.
Vijay Kumar (377076) +5 more
core +1 more source
Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors
Although beta-lactam allergies are an emerging focus of stewardship programs and interventions, less is publicly released regarding allergies to beta-lactamase inhibitors. This review presents and evaluates the data regarding allergic reactions with beta-
Kayla R. Stover +2 more
doaj +1 more source
New evidence in severe pneumonia: meropenem-vaborbactam
The appearance and spread of new mechanisms of bacterial resistance to antibiotics is a serious health problem. One of the most difficult resistance mechanisms to treat is the production of carbapenemases. Carbapenemase KPC is one of those mechanisms with few therapeutic options.
Forteza Guillot, Maria +2 more
openaire +3 more sources
Mutation of kvrA causes OmpK35/36 porin downregulation and reduced meropenem/vaborbactam susceptibility in KPC-producing Klebsiella pneumoniae [PDF]
Meropenem/vaborbactam resistance in Klebsiella pneumoniae is associated with loss of function mutations in the OmpK35 and OmpK36 porins. Here we identify two previously unknown loss of function mutations that confer cefuroxime resistance in K. pneumoniae.
Avison, Matthew B +5 more
core +1 more source
Introduction: The review aims to review the positioning of meropenem-vaborbactam in clinical practice, taking into consideration the characteristics of other available drugs, namely ceftazidime-avibactam, plazomicin, and colistin.
Giamarellos-Bourboulis, E.J. +2 more
core +1 more source
As meropenem-clavulanic acid is recommended for the treatment of drug-resistant tuberculosis, the repurposing of new carbapenem combinations may provide new treatment options, including oral alternatives.
Elin Economou Lundeberg +11 more
doaj +1 more source

